StockMarketWire.com - Angle said the University of Texas MD Anderson Cancer Center had developed a new technique for assessing the metastatic potential of breast cancer using the company's cell separation technology.

The technique Transmembrane Receptor Dynamics (TReD) measured the dynamics of cytoskeletal structure and mechanical properties of live cancer cells held within Angle's microfluidic Parsortix cassette using an optical interrogation technique, the company said.

'This offers the potential to differentiate highly invasive cancer cells from non to less-invasive cancer cells allowing more personalised treatment to be offered to the patient,' it added.

'This study is the 19th peer-reviewed publication by a leading independent cancer centre demonstrating successful use of ANGLE's world leading Parsortix CTC system.  We are pleased to see new applications of the system being developed by independent users of Parsortix, all of which add to the body of evidence and generate new commercial opportunities,' said ANGLE Founder and Chief Executive, Andrew Newland.





At 10:06am: [LON:AGL] Angle PLC share price was +1.5p at 70p



Story provided by StockMarketWire.com